<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="into consideration other factors (age, duration, ALT, disease stage). ALT," exact="alanine" post="aminotransferase; anti-HBc, antibody against hepatitis B core antigen; anti-HBe,"/>
 <result pre="DNA (+) Serological‘reverse seroconversion’ HBsAg (−)Anti-HBc (+) HBsAg (+) ALT," exact="alanine" post="aminotransferase; anti-HBc, antibody against hepatitis B core antigen; HBsAg,"/>
 <result pre="positivityNon-A HBV genotype Immunosuppression TypeDuration(see main text for details) ALT," exact="alanine" post="aminotransferase; anti-HBc, antibody against hepatitis B core antigen; HBeAg,"/>
 <result pre="(HR) has been reported at 5.1.25 Peak doses of &amp;gt;40 mg" exact="prednisolone" post="equivalents were associated with an adjusted HR for HBVr"/>
 <result pre="1 year and 5.5% at 10 years. GC peak daily dose &amp;gt;20 mg" exact="prednisolone" post="equivalents and treatment duration for &amp;gt;4 weeks were independent risk"/>
 <result pre="and expert advice suggests that daily doses of GCs &amp;gt;20 mg" exact="prednisolone" post="equivalents for treatment durations &amp;gt;4 weeks should be considered as"/>
 <result pre="and monitoring, rather than prophylaxis treatment, is advised. Non-biologic agents" exact="Methotrexate" post="and other conventional synthetic disease-modifying antirheumatic drugs Methotrexate (MTX)"/>
 <result pre="Non-biologic agents Methotrexate and other conventional synthetic disease-modifying antirheumatic drugs" exact="Methotrexate" post="(MTX) is an inhibitor of folate metabolism, and has"/>
 <result pre="synthetic disease-modifying antirheumatic drugs Methotrexate (MTX) is an inhibitor of" exact="folate" post="metabolism, and has served as the anchor drug for"/>
 <result pre="of MTX).35 With regards to other non-biologic agents such as" exact="leflunomide" post="(LEF), sulfasalazine (SSZ), hydroxychloroquine (HCQ), and azathioprine (AZA), cases"/>
 <result pre="With regards to other non-biologic agents such as leflunomide (LEF)," exact="sulfasalazine" post="(SSZ), hydroxychloroquine (HCQ), and azathioprine (AZA), cases of HBVr"/>
 <result pre="to other non-biologic agents such as leflunomide (LEF), sulfasalazine (SSZ)," exact="hydroxychloroquine" post="(HCQ), and azathioprine (AZA), cases of HBVr are extremely"/>
 <result pre="agents such as leflunomide (LEF), sulfasalazine (SSZ), hydroxychloroquine (HCQ), and" exact="azathioprine" post="(AZA), cases of HBVr are extremely rare, and these"/>
 <result pre="(MTX, LEF), appropriate monitoring precautions should always be in place." exact="Mycophenolate mofetil" post="Mycophenolate mofetil (MMF) is an oral inhibitor of de"/>
 <result pre="appropriate monitoring precautions should always be in place. Mycophenolate mofetil" exact="Mycophenolate mofetil" post="(MMF) is an oral inhibitor of de novo purine"/>
 <result pre="rheumatology field are limited, Li and colleagues compared a standard" exact="prednisone" post="regimen (1 mg/kg daily) versus MMF (500–1000 mg twice daily) and"/>
 <result pre="regimen (1 mg/kg daily) versus MMF (500–1000 mg twice daily) and lower" exact="prednisone" post="dose (0.5 mg/kg daily) in HBsAg-positive patients with idiopathic nephrotic"/>
 <result pre="in 64% (14/22) and 37% (7/19) of patients on standard" exact="prednisone" post="monotherapy and MMF/lower prednisone combination, respectively (p = 0.047), highlighting the"/>
 <result pre="37% (7/19) of patients on standard prednisone monotherapy and MMF/lower" exact="prednisone" post="combination, respectively (p = 0.047), highlighting the role of high GC"/>
 <result pre="main driver of HBVr in this cohort was an average" exact="prednisolone" post="daily dose of &amp;gt;5 mg. From these limited data, it"/>
 <result pre="as 53%, but was essentially nullified by the use of" exact="lamivudine" post="or entecavir. 63–65 In the setting of rheumatic diseases,"/>
 <result pre="with another currently under investigation (filgotinib). As for psoriatic arthritis," exact="tofacitinib" post="is the only JAK inhibitor currently approved for use"/>
 <result pre="is the only JAK inhibitor currently approved for use after" exact="methotrexate" post="or other csDMARD failure. Data for their HBVr potential"/>
 <result pre="the HBsAg positive patients were prophylactically treated with antivirals upon" exact="tofacitinib" post="initiation and did not experience HBVr. Amongst the four"/>
 <result pre="antivirals, two had HBVr after 6 and 12 months of" exact="tofacitinib" post="therapy, with one having only virological and the other"/>
 <result pre="were being cotreated with low-dose corticosteroids (5 and 10 mg of" exact="prednisolone" post="daily, respectively). Patients who were HBsAg negative/anti-HBc positive did"/>
 <result pre="of drug-related hepatotoxicity should be also of concern (especially for" exact="methotrexate" post="and leflunomide) and, thus, screening should be performed in"/>
 <result pre="be chosen after appropriate consultation. See text for details. ALT," exact="alanine" post="aminotransferase; anti-HBc, antibody against Hepatitis B core antigen; anti-HBs,"/>
 <result pre="antigen; HBV-DNA, HBV-deoxyribonucleic acid; HBVr, hepatitis B virus reactivation; TAF," exact="tenofovir alafenamide;" post="TDF, tenofovir disoproxil fumarate. Table 4. Risk of HBVr"/>
 <result pre="HCQ, hydroxychloroquine; IL, interleukin; JAK, Janus kinase; LEF, leflunomide; MMF," exact="mycophenolate mofetil;" post="MTX, methotrexate; RTX, Rituximab ; TNFi, tumor necrosis factor"/>
 <result pre="analogues (NAs) with high barrier to genetic resistance, such as" exact="entecavir" post="(ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF)"/>
 <result pre="resistance, such as entecavir (ETV), tenofovir disoproxil fumarate (TDF), and" exact="tenofovir alafenamide" post="(TAF) are the antiviral agents of choice (Figure 2).10,11"/>
 <result pre="al.A randomized, controlled trial of interferon alfa-2b alone and after" exact="prednisone" post="withdrawal for the treatment of chronic hepatitis B. The"/>
 <result pre="et al.Prednisolone priming enhances Th1 response and efficacy of subsequent" exact="lamivudine" post="therapy in patients with chronic hepatitis B. Hepatology2000; 32:"/>
 <result pre="B. Hepatology2000; 32: 604–609.10960456 22HoofnagleJHDavisGLPappasSC, et al.A short course of" exact="prednisolone" post="in chronic type B hepatitis. Report of a randomized,"/>
 <result pre="the tip of the iceberg?Hepatology2015; 61: 703–711.25412906 34LaohapandCArromdeeETanwandeeTLong-term use of" exact="methotrexate" post="does not result in hepatitis B reactivation in rheumatologic"/>
 <result pre="in vitro. J Viral Hepat1999; 6: 229–236.10607235 39YingCDe ClercqENeytsJRibavirin and" exact="mycophenolic acid" post="potentiate the activity of guanine- and diaminopurine-based nucleoside analogues"/>
 <result pre="Antiviral Res2000; 48: 117–124.11114413 40MaesBDvan PeltJFPeetersJC, et al.The effect of" exact="mycophenolate mofetil" post="on hepatitis B viral load in stable renal transplant"/>
 <result pre="with chronic hepatitis B. Transplantation2001; 72: 1165–1166.11579320 41Ben-AriZZemelRTur-KaspaRThe addition of" exact="mycophenolate mofetil" post="for suppressing hepatitis B virus replication in liver recipients"/>
 <result pre="suppressing hepatitis B virus replication in liver recipients who developed" exact="lamivudine" post="resistance-no beneficial effect. Transplantation2001; 71: 154–156.11211184 42LiXTianJWuJ, et al.A"/>
 <result pre="Transplantation2001; 71: 154–156.11211184 42LiXTianJWuJ, et al.A comparison of a standard-dose" exact="prednisone" post="regimen and mycophenolate mofetil combined with a lower prednisone"/>
 <result pre="42LiXTianJWuJ, et al.A comparison of a standard-dose prednisone regimen and" exact="mycophenolate mofetil" post="combined with a lower prednisone dose in chinese adults"/>
 <result pre="standard-dose prednisone regimen and mycophenolate mofetil combined with a lower" exact="prednisone" post="dose in chinese adults with idiopathic nephrotic syndrome who"/>
 <result pre="Arthritis Care Res2013; 65: 1504–1514. 46CarrollMBForgioneMAUse of tumor necrosis factor" exact="alpha" post="inhibitors in hepatitis B surface antigen-positive patients: a literature"/>
 <result pre="B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor" exact="alpha" post="therapy. Ann Rheum Dis2011; 70: 1719–1725.21719446 50ZingarelliSFrassiMBazzaniC, et al.Use"/>
 <result pre="Rheumatol2011; 21: 621–627.21528424 56CaporaliRBobbio-PallaviciniFAtzeniF, et al.Safety of tumor necrosis factor" exact="alpha" post="blockers in hepatitis B virus occult carriers (hepatitis B"/>
 <result pre="Intern Med2016; 164: 30–40.26595058 63HsuCHsiungCASuIJ, et al.A revisit of prophylactic" exact="lamivudine" post="for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a"/>
 <result pre="47: 844–853.18302293 64LauGKKYiuHHYFongDYT, et al.Early is superior to deferred preemptive" exact="lamivudine" post="therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology2003; 125:"/>
 <result pre="patients undergoing chemotherapy. Gastroenterology2003; 125: 1742–1749.14724827 65HuangHLiXZhuJ, et al.Entecavir vs" exact="lamivudine" post="for prevention of hepatitis B virus reactivation among patients"/>
 <result pre="Ann Hematol2011; 90: 1219–1223.21520001 71HuangY-HHsiaoL-THongY-C, et al.Randomized controlled trial of" exact="entecavir" post="prophylaxis for rituximab-associated hepatitis B virus reactivation in patients"/>
 <result pre="al.A patient with rheumatoid arthritis treated with tocilizumab together with" exact="lamivudine" post="prophylaxis after remission of infliximab-reactivated hepatitis B. Mod Rheumatol2011;"/>
 <result pre="a hepatitis B virus carrier successfully treated with secukinumab and" exact="entecavir" post="combination therapy. Eur J Dermatol2017; 27: 185–186.27965188 91FeasterBClineAFeldmanSRSecukinumab for"/>
</results>
